Upload
trananh
View
220
Download
1
Embed Size (px)
Citation preview
Acute myocardial infarction: Tracking
patients’ journeys and outcomes in a
complex, acute healthcare system
NHS Greater Glasgow and Clyde, Golden Jubilee
National Hospital, University of Glasgow, DataLab
and AstraZeneca UK
This analysis has been performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and Clyde (GGC), Golden Jubilee National
Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK Ltd.
Background
•Reducing cardiovascular mortality
and improving outcomes is a key
focus for NHS Scotland
•Scottish hospitals do not submit
data to Myocardial Ischaemia
National Audit Programme
(MINAP)
•We lack of contemporary data on
service delivery and outcome in
our patients.
Background
• In Glasgow, electronic patient records have been
implemented in place of paper records
• National Advisory Group for Heart Disease pilot e-Registry
• NHS Greater Glasgow and Clyde (GGC), Golden Jubilee
(GJNH), Glasgow Managed Clinical Network (GMCN) and
AstraZeneca UK (AZ)
= Joint Working Agreement
• MCN involves 6 acute hospitals in NHS GGC (population 1.2
million) and the regional hub for invasive cardiology (GJNH)
Pathway Map
Home
Local HospitalGJNH
Local A&E
1
2
3
4
56
9
Pathway Beginnings
1 – Emergency Direct to GJNH
2 – Local A&E to GJNH
3 – Direct Transfer from local Hospital to GJNH
4 – Elective GJNH admission following discharge and referral from local hospital
5 – Local Hospital only (no referral or GJNH admission)
6 – Elective GJNH admission only (no referral from local hospital or local admission)
Pathway Endings
A – Discharged home (from local or GJNH)
B – Transferred to local hospital before discharge
C – Death in hospital (local or GJNH)
Pilot Objectives
1. Design and create a linked CV patient registry for patients treated across
NHS GGC and GJNH using routinely collected electronic healthcare
records
2. Complete a service evaluation focusing upon the delivery 12 months of
ACS services managed across NHS GGC and the GJNH
3. Establish a robust legacy of quality data collection for CV patients that
can be used for research and service improvement purposes into the
future
4. Project steering committee to make recommendations for optimal
service design and local delivery plan to GMCN and National Advisory
Committee for Coronary Heart Disease
Key Early Activities
•Project steering group - NHS GGC, GJNH, GMCN & AstraZeneca UK
•Permissions from all relevant regional and national bodies
•Joint Working Framework –little financial resource needed
•Records extracted from three sources of electronic patient records from
NHS GGC and GJNH; initially for 3 month period to enable testing of
extract specification and process
•Pilot registry created by Safe Haven at University of Glasgow to link
records extracted
•Methodology for analyses and reports designed by AZ with support of
NHS clinical and technical teams
Pathway Definitions
Pathway Description Admission and Discharge Criteria Additional Criteria
1 Direct (emergency) to GJNHGJNH Admission method either 'Direct to Cardiac Centre‘ or 'Air ambulance transfer'
No referral prior to GJNH admission. Must havevalid discharge recorded
2 Via local A&E to GJNHGJNH Admission method either 'Ambulance to local A&E‘ or 'Self-referral to local A&E'
No referral prior to GJNH admission. Must havevalid discharge recorded
3Local hospital inpatient admission with direct transfer to GJNH
GJNH Admission method either 'Transfer from ward in local hospital’ or 'Already in cardiac centre'
Local Hospital admission and referral prior to GJNH admission. Must have valid discharge recorded.
4Local hospital inpatient admission, discharged home with referral to GJNH
GJNH Admission method either 'Elective admission‘ or 'Direct to cardiac centre'
Local Hospital admission and referral prior to GJNH admission. Local hospital discharge must be ‘Home’.
5 Local hospital treatment onlyAdmission direct to local hospital, dischargedhome or within local hospital
No referral for further activity after local hospital admission or evidence of GJNHadmission. Must have valid discharge recorded.
6 Elective GJNH treatment only
GJNH Admission method either 'Elective admission‘ or 'Direct to cardiac centre‘. Discharge method either 'Discharged home’ or 'Inpatient death'
No referral prior to GJNH admission or evidence of local hospital admission. Must have valid discharge recorded.
Summary of 12 month Data
TRAKCARE:
5445 records
SCI Gateway:
6651 records
CATHI:
7157 records
ExcludedSpells with incomplete data*
Non-IHD Final Diagnosis
*Incomplete Data: Pathway cannot be assigned due to missing information, normally due to start or end of pathway falling outside of current 12
month data window or patient attending from Health Board other than NHS GGC, therefore no TRAKCARE data available in current extract. Also
includes patients where SCI referral was made but there is no evidence of any clinical activity in dataset.
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
Mortality:
862 records
Ischaemic Heart Disease (IHD)
Linked Dataset
Unique Patients: 3186
Distinct Complete Spells: 3438
Example Outputs
9
Asset ID: 594,414.011 Date of Prep: November 2014
NSTEMI Summary
MINAP National Audit Annual Report 2013-141 NHS GGC Health Board Summary Oct 2013-Sept 2014
697 (63%) referred for or had angiography
451 (65%) admitted via emergency services or self-
presentation
48 (11%) angiography within 24hr of
admission
38 (8%) angiography 24-48hr after
admission
64 (14%) angiography 48-72hr after
admission
63 (14%) angiography 72-96hr after
admission
238 (53%) angiography >96 hr
after admission
200 (28%) admitted via transfer for specific
treatment
46 (7%) admitted via another or unknown
method
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
Non ST-Elevation Myocardial Infarction (NSTEMI)
NSTEMI Patients: Spells
by Care Pathway
N=1100
Local A&E
Local Hospital GJNH
Home
1n=30 (3%)
6n=46 (4%)
5n=403 (37%)
2n=6 (1%)
3n=415 (38%)
4n=200 (18%)
Pathway Definition
1 – Emergency Direct to GJNH
2 – Local A&E to GJNH
3 – Local hospital inpatient admission with direct
transfer to GJNH
4 – Local hospital inpatient admission, discharged
home with referral to GJNH
5 – Local Hospital only
6 – Elective GJNH only
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
2.2(median=1)
8.0(median=4)
7.3(median=6)
3.4(median=3)
11.4(median=6)
0.8(median=0.5)
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
1Direct to GJNH
(n=30)
2Local A&E to
GJNH
(n=6)
3Direct Transfer
(n=415)
4Discharged Home with
Referral(n=200)
5Local Hospital
Only
(n=403)
6Elective GJNH
Only
(n=46)
Mea
n D
ays
in H
osp
ital
Care Pathway
NSTEMI Patients: Mean Days in Hospital by Pathway N=1100
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
Notes: If a patient has an admission that lasts less than one day (i.e. Admitted and discharged on the same date) then for the purposes of calculation of days in hospital they
have been assigned a duration of 0.5 days for that admission.
99.1% 100.0% 100.0% 100.0% 100.0%
87.0%
49.8%
60.0%
83.3%
54.5%
36.0%
56.5%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
Any Pathway
(n=697)
1Direct to GJNH
(n=30)
2Local A&E to GJNH
(n=6)
3Direct Transfer
(n=415)
4Discharged Home
with Referral
(n=200)
6Elective GJNH Only
(n=46)
Pe
rce
nt
of
Spe
lls i
n t
he
Pat
hw
ay
Care Pathway
NSTEMI Patients: Percentage of Spells Receiving Angiography and Percentage Receiving PCI By Pathway
Angiography
PCI
N=697
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15-21 >21
1.Direct to GJNH 1.27 0.36 0.27 0.45 0.00 0.09 0.00 0.09 0.00 0.00 0.00 0.09 0.09 0.00 0.00 0.00 0.00
2.Local A&E to GJNH 0.00 0.09 0.00 0.09 0.18 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09
3.Direct Transfer 0.00 0.73 2.72 5.09 5.09 3.91 4.54 3.18 3.45 1.18 1.64 0.91 1.00 0.45 0.45 2.17 1.17
4.Discharged Home with Referral 0.00 1.09 3.27 7.55 3.64 1.55 0.64 0.18 0.09 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.09
5.Local Hospital Only 0.45 1.55 2.27 4.36 4.36 3.00 3.18 3.09 1.82 1.36 0.82 0.73 0.64 1.00 0.73 2.91 4.32
6.Elective GJNH Only 3.55 0.36 0.00 0.09 0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
Pe
rce
nt
of
Pa
tie
nts
Days in Hospital
N=1100
NSTEMI: Distribution of Days in
Hospital According to the Pathway
99.1% 100.0% 100.0% 100.0% 100.0%
87.0%
49.8%
60.0%
83.3%
54.5%
36.0%
56.5%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
Any Pathway
(n=697)
1Direct to GJNH
(n=30)
2Local A&E to GJNH
(n=6)
3Direct Transfer
(n=415)
4Discharged Home
with Referral
(n=200)
6Elective GJNH Only
(n=46)
Pe
rce
nt
of
Spe
lls i
n t
he
Pat
hw
ay
Care Pathway
NSTEMI Patients: Percentage of Spells Receiving Angiography and Percentage Receiving PCI By Pathway
Angiography
PCI
N=697
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
11.2(median=6)
0.6(median=0)
0.3(median=0)
5.0(median=4)
26.0(median=23)
-5.0
0.0
5.0
10.0
15.0
20.0
25.0
30.0
Any Pathway
(n=651)
1Direct to GJNH
(n=30)
2Local A&E to GJNH
(n=6)
3Direct Transfer
(n=415)
4Discharged Home
with Referral
(n=200)
Me
an D
ays
in t
o A
ngi
ogr
aph
y
Care Pathway
NSTEMI Patients: Mean Days from Acute Admission to Angiography
(Pathways 1-4)N=651
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
NHS Standard of Care < 72 hours
27%
38%
2%
26% 3%
3%
0%
10%
20%
30%
40%
50%
60%
<140(n=330)
≥140(n=252)
No Score(n=33)
Per
cen
t o
f Pat
ient
s R
efer
red
to G
JNH
GRACE ACS Risk Score Recorded at Time of Referral
NSTEMI Patients: GRACE Score for Patients Referred to GJNH from Local Hospital (Pathways 3 and 4)
4: Discharged Home with Referral
3: Direct Transfer
N=615
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
GRACE >140 criterion for referral
3.2% 3.4% 5.6% 7.9% 14.2%0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%
In Hospital(n=1100)
30 Days(n=941)
90 Days(n=941)
180 Days(n=771)
365 Days(n=288)
Mo
rtal
ity
Rat
e (
Pat
ien
ts w
ith
Dat
a)
Days From Most Recent Admission
NSTEMI Patients: All Cause Mortality (Unadjusted) N=1100
NB – Only for patients with sufficient follow-up for each timeframe
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
2.3% 2.6% 4.0% 4.7% 8.3%0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
In Hospital(n=1100)
30 Days(n=941)
90 Days(n=941)
180 Days(n=771)
365 Days(n=288)
Mo
rtal
ity
Rat
e (
Pat
ien
ts w
ith
Dat
a)
Days From Most Recent Admission
NSTEMI Patients: Mortality of Cardiovascular Cause (Unadjusted)
N=1100
NB – Only for patients with sufficient follow-up for each timeframe
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
1.9% 2.3% 3.3% 3.9% 6.9%0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
In Hospital(n=1100)
30 Days(n=941)
90 Days(n=941)
180 Days(n=771)
365 Days(n=288)
% o
f D
eat
hs
in P
atie
nts
wit
h D
ata
Days From Most Recent Admission
NSTEMI Patients: Mortality Due to Ischaemic Heart Disease (Unadjusted)
N=1100
NB – Only for patients with sufficient follow-up for each timeframe
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
7(median=5)
8(median=6)
7(median=4)
9(median=5)
10(median=5)
8(median=4)
0
2
4
6
8
10
12
14
Glasgow Royal Infirmary(n=289)
Inverclyde Royal Hospital(n=93)
Royal Alexandra Hospital(n=195)
Southern General Hospital(n=59)
Victoria Infirmary(n=161)
Western/Gartnavel Hospitals(n=193)
Mea
n D
ays
in H
osp
ital
NHS GGC Hospital of Origin
NSTEMI Patients: Mean Days in Hospital by Originating Hospital
Vale of Leven Hospital not shown due to low patient numbers (n=2 )
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
Analysis performed by AstraZeneca as part of the Joint Working project between NHS Greater Glasgow and
Clyde (GGC), Golden Jubilee National Hospital (GJNH), GGC Managed Clinical Network and AstraZeneca UK
Ltd.
2
3
2
2
3
3
3
3
4
3
4
3
0 5 10 15 20 25 30 35
Glasgow Royal Infirmary(n=141)
Inverclyde Royal Hospital(n=45)
Royal Alexandra Hospital(n=81)
Southern General Hospital(n=22)
Victoria Infirmary
(n=39)
Western/Gartnavel Hospitals
(n=78)
Mean Days
Re
ferr
ing
Ho
spit
al
NSTEMI Patients Referred with Direct Transfer: Mean Time from Admission to Referral and
from Referral to Treatment by Referring Hospital
Time to Referral
Time from Referral to Treatment
2
3
2
2
3
2
25
14
30
20
22
18
0 5 10 15 20 25 30 35
Glasgow Royal Infirmary(n=50)
Inverclyde Royal Hospital(n=5)
Royal Alexandra Hospital
(n=47)
Southern General Hospital
(n=14)
Victoria Infirmary(n=44)
Western/Gartnavel Hospitals(n=33)
Mean Days
Re
ferr
ing
Ho
spit
al
NSTEMI Patients Referred via Discharge Home: Mean Time from Admission to Referral and
from Referral to Treatment by Referring Hospital Time to Referral
Time from Referral to Treatment
Moving forward
Aims and objectives for next 12 months
1. Regional ACS eRegisty with automated data collation and reporting systems
2. Development and exploration of expanded dataset to identify new group or pathways of care of clinical significance, e.g. Ambulance Service
3. Investigate additional data sources that could be integrated into the registry to improve the richness of the data
Innovation in Data Science
Key tenet of SG policy as described in CMO Realistic Medicine publication is “Reducing Variation” but it first needs to be measured
Provide a paradigm shift by developing a timely, on demand real time reporting tool
Immediate focus is GGC & GNJ HB but adaptable nationally
Develop reporting to suit Scottish perspective / needs
Use different data science techniques to explore potential groups or patterns of care of clinical interest
Link to wider datasets to provide richer more detailed information on care and long term outcomes
Real-time on demand reporting
Mortality
CATHi Lab
Scottish
Ambulance
Service
SCI-Gateway
TRAKCare
Approved
NHS Staff
using
existing
software
and access
rights
eRegistry
Dataset
NHS datasets NHS Safe Haven
NHS
Server 1- Linked
identified
datasets
SLA for
data
supply
ETL &
process of
data
Da
ta r
ep
ort
ing
Data Science /
Link to wider datasets
Mortality
CATHi Lab
Scottish
Ambulance
Service
SCI-Gateway
TRAKCare
Approved
researchers in
controlled
Safe Haven
environment
eRegistry
Dataset
NHS datasets NHS Safe HavenServer 1- Linked
identified
datasets
SLA for
data
supplyETL &
process of
data
LP
AC
Ap
pro
ve
d D
ata
ex
tra
cts
Server 2- Linked
anonymised
datasets
Other
datasets
Innovation in Data Science
Apply novel techniques (e.g.
Bayesian techniques, machine
learning, pattern recognition
etc) to derive new insight in
support of clinical decision-
making
Long term outcomes
University of Glasgow MVLS Industrial Partnership PhD with AstraZeneca
Aim: to explore the association of socio-economic status with the process and long-term outcomes of treatment for suspected acute MI
Use data linkage to undertake epidemiological research to better understand the patient journey and factors which influence treatment decisions and outcomes.
The Learning Health System
Next steps
1. Share the outputs – NHS Scotland
2. National Steering Group in Scottish Cardiac Society
3. Support other Boards to develop their own e-Registry, potentially through
Safe Haven
4. National e-Registry
5. Beyond MINAP – all cardiovascular hospitalisation.
Learnings
1. Both clinical and technical representation in steering group is essential to
ensure understanding and delivery of requirements
2. Strong project management needed to drive project forwards to meet
milestones
3. Validation of data (both underlying source and analysis assumptions) is
worth investing in
4. It is possible to create a quality patient registry from existing data
sources, without the need for additional data collection or excessive use
of NHS resources
5. Joint Working between the NHS, academia, and the pharmaceutical
industry can facilitate the delivery of projects that are valuable to the
NHS and patients
Thank you for your attention